Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 19/20 | 0.58 |
| ▸ | KDR | P35968 | 8/20 | 0.57 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 2/20 | 0.56 |
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 3/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405511 | 0.86 | FAAH (0.66) | METKDRRETKITFLT3 | |
| SCHEMBL16136597 | 0.83 | MET (0.67) | METKDRRETKITFLT3 | |
| SCHEMBL4402823 | 0.82 | MET (0.86) | METKDRRETKITFLT3 | |
| SCHEMBL13615636 | 0.81 | MET (0.59) | METKDRRETKITFLT3 | |
| SCHEMBL16381016 | 0.80 | MET (0.59) | METKDRRETKITFLT3 | |
| SCHEMBL26075853 | 0.80 | MET (0.58) | METKDRRETKITFLT3 | |
| SCHEMBL15580185 | 0.79 | MET (0.51) | METKDRRETKITFLT3 | |
| SCHEMBL22521226 | 0.79 | HDAC2 (0.84) | METKDRRETKITFLT3 | |
| SCHEMBL16069961 | 0.78 | MET (0.58) | METKDRRETKITFLT3 | |
| SCHEMBL12164847 | 0.77 | S1PR4 (0.52) | KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140221372-A1 | METHOD OF ADMINISTRATION AND TREATMENT | GlaxoSmithKline Intellectual Property (NO 2.) Limited (GB) | 2014-08-07 | — | — | US | disclosed |
| WO-2014093750-A1 | METHOD OF ADMINISTRATION AND TREATMENT | GLAXOSMITHKLINE LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| US-20130252956-A1 | METHODS OF TREATING CANCER | EXELIXIS, INC. | 2013-09-26 | — | — | US | disclosed |
| US-20130150363-A1 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor | GLAXOSMITHKLINE (US) | 2013-06-13 | — | — | US | disclosed |
| US-20130142790-A1 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor | GLAXOSMITHKLINE (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2012071321-A1 | METHOD OF TREATING CANCER | GLAXOSMITHKLINE LLC (US) | 2012-05-31 | — | — | WO | disclosed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| WO-2009137429-A1 | METHOD OF TREATING CANCER USING A CMET AND AXL INHIBITOR AND AN ERBB INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090274693-A1 | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor | EXELIXIS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252956-A1 | METHODS OF TREATING CANCER | HRAS, TP53, HCCS | MET 54/4885KDR 3034/4885RET 1428/4885 |
| US-20140221372-A1 | METHOD OF ADMINISTRATION AND TREATMENT | MET, SLCO1B3, SLCO2B1 | MET 1/4885KDR 75/4885RET 7/4885 |
| US-20090274693-A1 | Method of Treating Cancer using a cMet and AXL Inhibitor and an ErbB Inhibitor | ERBB3, ERBB2, EGFR | MET 8/4885KDR 46/4885RET 5/4885 |
| US-20130142790-A1 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor | ERBB3, ERBB2, EGFR | MET 8/4885KDR 49/4885RET 6/4885 |
| US-20130150363-A1 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor | ERBB3, ERBB2, EGFR | MET 8/4885KDR 46/4885RET 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.